DYRK1A inhibitors leucettines and TGF-β inhibitor additively stimulate insulin production in beta cells, organoids, and isolated mouse islets
PLOS ONE · 17.05.2023 · 18 (5) · e0285208
DOI: 10.1371/journal.pone.0285208 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 17.05.2023. Verfasst von Barbara Pucelik und 2 weiteren Autor:innen. Beteiligte Einrichtung: Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa, Krakow, Poland. Hauptthemen laut MEDLINE: Insulin-Secreting Cells, Islets of Langerhans, Pancreatic Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Narodowe Centrum Nauki, Uniwersytet Jagielloński w Krakowie, NAWA Polish Returns 2018.
Abstract (Originalsprache)
The decreased β-cell mass and impaired β-cell functionality are the primary causes of diabetes mellitus (DM). Nevertheless, the underlying molecular mechanisms by which β-cell growth and function are controlled are not fully understood. In this work, we show that leucettines, known to be DYRK1A kinase inhibitors, can improve glucose-stimulated insulin secretion (GSIS) in rodent β-cells and isolated islets, as well as in hiPSC-derived β-cells islets. We confirm that DYRK1A is expressed in murine insulinoma cells MIN6. In addition, we found that treatment with selected leucettines stimulates proliferation of β-cells and promotes MIN6 cell cycle progression to the G2/M phase. This effect is also confirmed by increased levels of cyclin D1, which is highly responsive to proliferative signals. Among other leucettines, leucettine L43 had a negligible impact on β-cell proliferation, but markedly impair GSIS. However, leucettine L41, in combination with LY364947, a, a potent and selective TGF-β type-I receptor, significantly promotes GSIS in various cellular diabetic models, including MIN6 and INS1E cells in 2D and 3D culture, iPSC-derived β-cell islets derived from iPSC, and isolated mouse islets, by increased insulin secretion and decreased glucagon level. Our findings confirm an important role of DYRK1A inhibitors as modulators of β-cells function and suggested a new potential target for antidiabetic therapy. Moreover, we show in detail that leucettine derivatives represent promising antidiabetic agents and are worth further evaluation, especially in vivo .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa, Krakow, Poland.
- Doctoral School of Exact and Natural Sciences, Jagiellonian University, Krakow, Poland.
ORCID-Profile: Barbara Pucelik, Anna Czarna
Förderung
- Narodowe Centrum Nauki
- Uniwersytet Jagielloński w Krakowie
- NAWA Polish Returns 2018
Zitieren
APA
Pucelik, B., Barzowska, A., & Czarna, A. (2023). DYRK1A inhibitors leucettines and TGF-β inhibitor additively stimulate insulin production in beta cells, organoids, and isolated mouse islets. PLOS ONE, 18(5), e0285208. https://doi.org/10.1371/journal.pone.0285208
Vancouver
Pucelik B, Barzowska A, Czarna A. DYRK1A inhibitors leucettines and TGF-β inhibitor additively stimulate insulin production in beta cells, organoids, and isolated mouse islets. PLOS ONE. 2023;18(5):e0285208. doi:10.1371/journal.pone.0285208
BibTeX
@article{Pucelik2023,
author = {Pucelik, Barbara and Barzowska, Agata and Czarna, Anna},
title = {DYRK1A inhibitors leucettines and TGF-β inhibitor additively stimulate insulin production in beta cells, organoids, and isolated mouse islets},
journal = {PLOS ONE},
year = {2023},
volume = {18},
number = {5},
pages = {e0285208},
doi = {10.1371/journal.pone.0285208}
}
EUVIMED